Comparative Pharmacology
Head-to-head clinical analysis: IOHEXOL versus IOPAMIDOL 250.
Head-to-head clinical analysis: IOHEXOL versus IOPAMIDOL 250.
IOHEXOL vs IOPAMIDOL-250
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-ionic, water-soluble, iodinated contrast agent that increases the radiopacity of vascular structures and body cavities, allowing visualization during radiographic procedures. It does not bind to serum proteins and is rapidly distributed in extracellular fluid.
Iopamidol is a non-ionic, water-soluble, iodinated radiographic contrast agent that attenuates X-rays, thereby enhancing vascular and tissue contrast during imaging procedures. It acts by increasing the radiodensity of blood vessels and organs.
Intravenous: 300-370 mg iodine/kg (0.3-0.37 mL/kg of 300 mg I/mL solution) for contrast imaging; typical range 15-150 mL per procedure depending on examination. Intra-arterial: Doses vary by procedure, typically 1-10 mL total. Do not exceed 3 mL/kg total dose.
1-2 mL/kg intravenously for contrast imaging, not to exceed 200 mL total; dose and rate vary by procedure and patient weight.
None Documented
None Documented
Clinical Note
moderateIohexol + Metformin
"The risk or severity of adverse effects can be increased when Iohexol is combined with Metformin."
Terminal elimination half-life approximately 2-3 hours in patients with normal renal function. In patients with severe renal impairment (CrCl <30 mL/min), half-life may be prolonged up to 30-60 hours, necessitating dose adjustment or avoidance.
Terminal half-life 1.5-2 hours in normal renal function; may extend to 5-10 hours in severe renal impairment (CrCl <30 mL/min)
Primarily renal via glomerular filtration; 90-100% of administered dose excreted unchanged in urine within 24 hours. Less than 2% excreted in feces. Biliary excretion negligible (<1%).
Renal: >90% unchanged via glomerular filtration; biliary/fecal: <2%
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent